Literature DB >> 17845581

Eosinophilic inflammation: mechanisms regulating IL-5 transcription in human T lymphocytes.

J Wang1, I G Young.   

Abstract

BACKGROUND: Interleukin (IL)-5 is a key regulator of eosinophilia in allergic inflammation and parasite infections but the mechanisms regulating IL-5 expression in activated human T lymphocytes are poorly understood. From studies on mouse cells, the activation protein (AP)-1 and GATA-3 sites in the proximal promoter region appear to be important in IL-5 regulation but the significance of an adjacent Ets/nuclear factor of activated T cell (NFAT) site has been less clear.
METHODS: Interleukin-5 transcriptional activity was measured by transfection of reporter genes into the human HSB-2 cells and normal T lymphocytes. Expression vectors encoding transcription factors were used for transactivation studies and IL-5 expression measured using reporter genes and mRNA levels. Transcription factor binding was shown with chromatin immunoprecipitation (ChIP).
RESULTS: HSB-2 cells showed high inducible expression of IL-5 mRNA. Mutation of reporter gene plasmids showed the Ets/NFAT site was of equal importance to the AP-1 and GATA-3 sites in regulating IL-5 transcription. Transactivation by Ets1 increased luciferase expression 15-fold, in the absence of stimulation, and AP-1 (c-Fos/c-Jun) and GATA-3 gave transactivations of 85-fold, and 100-fold, respectively. Synergistic interactions were demonstrated between Ets1, GATA-3 and AP-1. Dominant-negative AP-1 inhibited IL-5 transcription. Transactivation by GATA-3 and synergy between GATA-3, Ets1 and AP-1 were verified measuring IL-5 mRNA levels. Chromatin immunoprecipitation showed increased binding of Ets1 and GATA-3 to the IL-5 promoter after stimulation. The importance of the Ets1 site and of synergistic interactions between the three transcription factors were verified with primary human T cells.
CONCLUSION: Ets1, GATA-3 and AP-1 synergize to regulate IL-5 transcription in human T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845581     DOI: 10.1111/j.1398-9995.2007.01510.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

1.  Differences in the T-bet and GATA-3 expression patterns between lymphocytic colitis and coeliac disease.

Authors:  Korinna Jöhrens; Maria Grünbaum; Ioannis Anagnostopoulos
Journal:  Virchows Arch       Date:  2010-08-31       Impact factor: 4.064

2.  Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.

Authors:  Stephen D Zucker; Megan E Vogel; Tammy L Kindel; Darcey L H Smith; Gila Idelman; Uri Avissar; Ganesh Kakarlapudi; Michelle E Masnovi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-17       Impact factor: 4.052

3.  Functional characterization of an eosinophil-specific galectin, ovine galectin-14.

Authors:  Anna R Young; Garry J Barcham; Joanna M Kemp; Jillian L Dunphy; Andrew Nash; Els N Meeusen
Journal:  Glycoconj J       Date:  2008-09-23       Impact factor: 2.916

4.  Phylogenetic and functional analysis identifies Ets-1 as a novel regulator of the Th2 cytokine gene locus.

Authors:  Jannine M Strempel; Roland Grenningloh; I-Cheng Ho; Donata Vercelli
Journal:  J Immunol       Date:  2009-12-28       Impact factor: 5.422

5.  A retrospective cross-sectional study of risk factors and clinical spectrum of children admitted to hospital with pandemic H1N1 influenza as compared to influenza A.

Authors:  Shaun K Morris; Patricia Parkin; Michelle Science; Padmaja Subbarao; Yvonne Yau; Sean O'Riordan; Michelle Barton; Upton D Allen; Dat Tran
Journal:  BMJ Open       Date:  2012-03-11       Impact factor: 2.692

6.  Identification and association of the single nucleotide polymorphisms, C-509T, C+466T and T+869C, of the TGF-β1 gene in patients with asthma and their influence on the mRNA expression level of TGF-β1.

Authors:  Michał Panek; Tadeusz Pietras; Artur Fabijan; Jan Zioło; Lukasz Wieteska; Beata Małachowska; Wojciech Fendler; Janusz Szemraj; Piotr Kuna
Journal:  Int J Mol Med       Date:  2014-08-11       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.